Hyponatremia – unfavourable prognostic factor in hepatic cirrhosis
| Autor: | Vlad Pădureanu, Andreea Larisa Moraru, P Mitruţ, Anca Ştefania Enescu, Octavia Ileana Petrescu, Aurelia Enescu, F Petrescu, Valeria Carmen Albu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Prognostic factor medicine.medical_specialty Cirrhosis endocrine system diseases hyponatremia liver cirrhosis Central nervous system Disease Gastroenterology Water consumption Cerebral edema End Stage Liver Disease 03 medical and health sciences 0302 clinical medicine hepatic transplant Internal medicine medicine Humans antidiuretic hormone urogenital system business.industry digestive oral and skin physiology portal hypertension nutritional and metabolic diseases medicine.disease RC31-1245 Rheumatology 030104 developmental biology medicine.anatomical_structure 030211 gastroenterology & hepatology Hyponatremia business |
| Zdroj: | Romanian Journal of Internal Medicine, Vol 54, Iss 4, Pp 207-210 (2016) |
| ISSN: | 2501-062X |
| Popis: | Hyponatremia is defined by a level of Na in serum below or equal to 136 mEq/L while in hepatic cirrhosis it is classically considered as relevant only at a level of Na below 130 mEq/L. Hyponatremia frequently occurs in patients with end-stage hepatic disease. The frequency and severity are variable but it has been estimated that it occurs with a frequency of 57% in hospitalized patients with cirrhosis and in those on waiting lists for hepatic transplants. Signs and symptoms of hyponatremia are related to dysfunctions of the central nervous system, due to migration of the water from intravascular space to the brain cells, resulting in the occurrence of cerebral edema. Therapeutic options in hyponatremia are limited and are based on restriction of water consumption, exclusion of diuretics and vaptans. Hepatic transplant remains the only definitive treatment for end-stage hepatic diseases in which hyponatremia has occurred. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|